PM

Pardeep Mehta

Active Director Director DIN 09293867
DIN 09293867 First appointment Sep 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2021
Shareholding value •••• Premium profile

About Pardeep Mehta

Data last updated:

Pardeep Mehta is a Director at Dzire Pharmaceuticals Private Limited (since 2021). The company operates in Pharma. Dzire Pharmaceuticals Private Limited reported revenue of ₹2.11 Cr (FY 2025).

DIN 09293867
Primary Designation Director
Industry Pharma
First Appointment 17 Sep 2021
Oldest Company Age 13 yrs
Largest company Dzire Pharmaceuticals Private Limited · ₹2.11 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director17 Sep 20212013₹2.11 Cr (FY 2025)Active

Board colleagues of Pardeep Mehta

NameDINCompanyDesignation
Bhim Mehta06894164Dzire Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Dzire Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Pardeep Mehta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pardeep Mehta

Pardeep Mehta currently holds 1 directorship: Dzire Pharmaceuticals Private Limited (Director, since 17 Sep 2021, revenue ₹2.11 Cr (FY 2025)).

Pardeep Mehta was first appointed on 17 Sep 2021 as Director at Dzire Pharmaceuticals Private Limited.

The current boards of Pardeep Mehta's companies include Bhim Mehta (Dzire Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available